natgillin/translations-raw huggingface dataset:
An overall favourable response required meeting each of 5 criteria: (1) successful treatment of any baseline fungal infection (caspofungin 51.9 % [14/27], liposomal amphotericin B 25.9 % [7/27]), (2) no breakthrough fungal infections during administration of study drug or within 7 days after completion of treatment (caspofungin 94.8 % [527/556], liposomal amphotericin B 95.5 % [515/539]), (3) survival for 7 days after completion of study therapy (caspofungin 92.6 % [515/556], liposomal amphotericin B 89.2 % [481/539]), (4) no discontinuation from the study drug because of drug-related toxicity or lack of efficacy (caspofungin 89.7 % [499/556], liposomal amphotericin B 85.5 % [461/539]), and (5) resolution of fever during the period of neutropaenia (caspofungin 41.2 % [229/556], liposomal amphotericin B 41.4 % [223/539]). 
Celotni odziv je bil ocenjen kot ugoden, če je bilo izpolnjenih vseh 5 naslednjih meril: (1) uspešno zdravljenje katerekoli osnovne glivne okužbe (kaspofungin 51,9 % [14/27], liposomski amfotericin B 25,9 % [7/27]), (2) brez izbruha glivnih okužb med uporabo študijskega zdravila in 7 dni po zaključku zdravljenja (kaspofungin 94,8 % [527/556], liposomski amfotericin B 95,5 % [515/539]), (3) preživetje 7 dni po zaključku raziskovane terapije (kaspofungin 92,6 % [515/556], liposomski amfotericin B 89,2 % [481/539]), (4) brez prekinitve raziskovanega zdravila zaradi z njim povezane toksičnosti ali nezadostne učinkovitosti (kaspofungin 89,7 % [499/556], liposomski amfotericin B 85,5 % [461/539]), (5) izginotje zvišane telesne temperature med obdobjem nevtropenije (kaspofungin 41,2 % [229/556], liposomski amfotericin B 41,4 % [223/539]).
This infusion solution must be used within 24 hours if stored at or below 25°C or within 48 hours if stored refrigerated at 2 to 8°C. 
Raztopino za infundiranje je treba uporabiti v 24 urah, če je shranjena pri temperaturi 25 °C ali manj, ali v 48 urah, če je shranjena na hladnem pri temperaturi od 2 do 8 °C.
• Abnormal skin tissue, generalised itching, hives, rash of varying appearance, abnormal skin, red often itchy spots on your arms and legs and sometimes on the face and the rest of the body 
• nenormalno kožno tkivo, srbenje po celem telesu, koprivnica, različni izpuščaji, nenormalna koža, rdeče in pogosto srbeče lise na okončinah ter včasih na obrazu in ostalem delu telesa
Paediatric Patients 
Pediatrični bolniki
Moderate (creatinine clearance 31 to 49 mL/min), advanced (creatinine clearance 5 to 30 mL/min), and end-stage (creatinine clearance <10 mL/min and dialysis dependent) renal impairment moderately increased caspofungin plasma concentrations after single-dose administration (range: 30 to 49 % for AUC). 
Zaradi zmerne okvare (kreatininski očistek 31 do 49 ml/min), napredovale okvare (kreatininski očistek 5 do 30 ml/min) in končne ledvične odpovedi (kreatininski očistek < 10 ml/min in na dializi) se je plazemska koncentracija kaspofungina po enem odmerku zmerno povečala (razpon: za 30 do 49 % AUC).
No dosage adjustment is necessary based on renal impairment (see section 5.2). 
Prilagoditev odmerka glede na ledvično okvaro ni potrebna (glejte poglavje 5.2).
For adult patients with moderate hepatic impairment (Child-Pugh score 7 to 9), Caspofungin 35 mg daily is recommended based upon pharmacokinetic data. 
Pri odraslih bolnikih z zmerno jetrno okvaro (stopnja Child-Pugh 7 do 9 točk) glede na farmakokinetične podatke priporočamo kaspofungin v odmerku 35 mg dnevno.
The favourable response rate, by indication, at the end of caspofungin therapy was as follows in the MITT analysis: 81 % (30/37) in invasive candidiasis, 50 % (5/10) in invasive aspergillosis, and 100 % (1/1) in esophageal candidiasis. 
Deleži ugodnega odziva za posamezno indikacijo so bili na koncu zdravljenja s kaspofunginom v analizi MITT naslednji: 81 % (30/37) pri invazivni kandidiazi, 50 % (5/10) pri invazivni aspergilozi in 100 % (1/1) pri ezofagealni kandidiazi.
In limited clinical experience, resistance to caspofungin in patients with invasive aspergillosis has been observed. 
V omejenih kliničnih izkušnjah so pri bolnikih z invazivno aspergilozo opazili rezistenco na kaspofungin.
Other medicines and Caspofungin Accord 
Druga zdravila in zdravilo Kaspofungin Accord
Race: Patient pharmacokinetic data indicated that no clinically significant differences in the pharmacokinetics of caspofungin were seen among Caucasians, Blacks, Hispanics, and Mestizos. 
Rasa: Farmakokinetični podatki pri bolnikih so pokazali, da ni bilo klinično pomembnih razlik v farmakokinetiki kaspofungina pri belcih, črncih, Latinoameričanih ter mešancih belih in indijanskih staršev.
Distribution plays the prominent role in caspofungin plasma pharmacokinetics and is the rate-controlling step in both the alpha- and beta-disposition phases. 
Porazdelitev ima pomembno vlogo v plazemski farmakokinetiki kaspofungina in določa hitrost obeh - faze alfa in faze beta razporeditve.
If you are not sure, talk to your doctor, nurse or pharmacist before you are given your medicine. 
Če ste negotovi, se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom, preden začnete uporabljati vaše zdravilo.
• Fast heart beat 
• hiter srčni utrip
Rifampicin caused a 60 % increase in AUC and 170 % increase in trough concentration of caspofungin on the first day of co-administration when both medicinal products were initiated together in healthy adult volunteers. 
Rifampicin je pri zdravih odraslih prostovoljcih prvi dan sočasnega zdravljenja s kaspofunginom povzročil 60 % povečanje AUC kaspofungina in 170 % zvečanje koncentracije kaspofungina, izmerjene tik pred naslednjim odmerkom, če je bilo zdravljenje z obema zdraviloma uvedeno hkrati.
The maximum loading dose on Day 1 should not exceed 70 mg regardless of the patient's calculated dose. 
Največji uvajalni odmerek 1. dan ne sme preseči 70 mg, ne glede na izračunani odmerek za bolnika.
DO NOT MIX OR CO-INFUSE CASPOFUNGIN ACCORD WITH ANY OTHER MEDICINES, as there are no data available on the compatibility of Caspofungin Accord with other intravenous substances, additives, or medicinal products. 
ZDRAVILA KASPOFUNGIN ACCORD NE MEŠAJTE IN NE INFUNDIRAJTE SKUPAJ S KATERIMKOLI DRUGIM ZDRAVILOM, ker ni podatkov o kompatibilnosti zdravila Kaspofungin Accord in drugih substanc, aditivov in zdravil za intravensko uporabo.
Fungicidal activity with caspofungin has been demonstrated against Candida yeasts. 
Fungicidno delovanje kaspofungina je bilo dokazano proti kvasovkam vrste Candida.
Caspofungin is not dialysable. 
Kaspofungin se ne dializira.
Two intermediate products, formed during the degradation of caspofungin to this open ring compound, form covalent adducts to plasma proteins resulting in a low-level, irreversible binding to plasma proteins. 
Dva vmesna presnovka, ki nastaneta tekom razgradnje v spojino z odprtim obročem, tvorita kovalentne adukte s plazemskimi proteini, ki predstavljajo majhen delež ireverzibilne povezave s plazemskimi proteini.
Phlebitis was a commonly reported local injection-site adverse reaction in all patient populations. 
Flebitis je bil pogost neželeni učinek na mestu vboda pri vseh populacijah bolnikov.
Stability data have shown that the concentrate for solution for infusion can be stored for up to 24 hours when the vial is stored at 25°C or less and reconstituted with water for injections. 
Stabilnostni podatki kažejo, da koncentrat za pripravo raztopine za infundiranje, ki smo ga pripravili z vodo za injekcije, lahko shranjujemo do 24 ur pri temperaturi 25 °C ali manj.
The favourable response rates for patients who were either refractory to or intolerant of previous therapies were 36 % (19/53) and 70 % (7/10), respectively. 
Delež ugodnega odziva je pri bolnikih, ki se na prejšnje zdravljenje niso odzvali, znašal 36 % (19/53), med bolniki, ki prejšnjega zdravljenja niso prenašali, pa 70 % (7/10).
Investigations decreased potassium, hypomagnesemia, increased glucose, decreased phosphorus, and increased phosphorus 
Preiskave znižane vrednosti kalija, hipomagneziemija, zvišane vrednosti glukoze, znižane vrednosti fosforja in zvišane vrednosti fosforja
Standard preparation (reconstituted Caspofungin Accord added to 250 mL) final concentration 
Standardna priprava (koncentrat zdravila Kaspofungin Accord dodan v 250 ml) končna koncentracija
• Changes in some laboratory blood tests (including increased values of some liver tests) 
• spremembe nekaterih laboratorijskih izvidov krvi (vključno s povečanimi vrednostmi nekaterih jetrnih testov)
• Flushing, hot flush, high blood pressure, low blood pressure, redness along a vein which is extremely tender when touched 
• zardevanje, naval vročine, visok krvni tlak, nizek krvni tlak, rdečina na mestu ob veni, ki je izredno občutljivo na dotik
Caspofungin 50 mg once daily was administered following a 70 mg loading dose, while amphotericin B was administered at 0.6 to 0.7 mg/kg/day to non-neutropaenic patients or 0.7 to 1.0 mg/kg/day to neutropaenic patients. 
Kaspofungin so po 70 mg uvajalnem odmerku uporabljali v odmerku 50 mg enkrat na dan. Amfotericin B so pri nenevtropeničnih bolnikih uporabljali v odmerku 0,6 do 0,7 mg/kg/dan, pri nevtropeničnih pa v odmerku 0,7 do 1,0 mg/kg/dan.
• Women given Caspofungin Accord should not breast-feed. 
• Ženske, ki uporabljajo zdravilo Kaspofungin Accord, ne smejo dojiti.
Of note, the efficacy and safety of caspofungin have not been adequately studied in prospective clinical trials involving neonates and infants under 3 months of age. 
Opozoriti je treba, da učinkovitost in varnost kaspofungina nista bili dovolj raziskani v prospektivnih kliničnih preskušanjih pri novorojenčkih in dojenčkih, mlajših od 3 mesecev.
Therapy should be continued until up to 72 hours after resolution of neutropaenia (ANC≥500). 
Zdravljenje se mora nadaljevati še 72 ur po tem, ko nevtropenija izgine (absolutno število nevtrofilcev ≥ 500).
What Caspofungin Accord looks like and contents of the pack Caspofungin Accord powder for concentrate for solution for infusion is a white to off-white powder. 
Izgled zdravila Kaspofungin Accord in vsebina pakiranja Kaspofungin Accord prašek za koncentrat za raztopino za infundiranje je bel do skoraj bel prašek.
Aseptically add 10.5 mL of water for injection.a This reconstituted solution may be stored for up to 24 hours at or below 25°C.b This will give a final caspofungin concentration in the vial of 
Aseptično dodajte 10,5 ml vode za injekcije.a Pripravljeno raztopino lahko shranite za največ 24 ur pri temperaturi 25 °C ali manj.b Končna koncentracija kaspofungina v viali bo tako
You will be given Caspofungin Accord: 
Zdravilo Kaspofungin Accord boste prejeli:
Invasive Candidiasis in Adult Patients: Two hundred thirty-nine patients were enrolled in an initial study to compare caspofungin and amphotericin B for the treatment of invasive candidiasis. 
Invazivna kandidiaza pri odraslih bolnikih: V prvotno študijo, ki je primerjala kaspofungin in amfotericin B pri zdravljenju invazivne kandidiaze, je bilo vključenih 239 bolnikov.
The overall success rates in the MITT analysis results, adjusted by risk strata, were as follows: 46.6 % (26/56) for caspofungin and 32.2 % (8/25) for liposomal amphotericin B. 
analize, prilagojenih glede na stratume tveganja, sta bila: 46,6 % (26/56) za kaspofungin in 32,2 % (8/25) za liposomski amfotericin B.
For caspofungin, there were no effects on fertility in studies conducted in male and female rats (see section 5.3). 
V študijah, izvedenih na samcih in samicah podgan, kaspofungin ni imel učinkov na plodnost (glejte poglavje 5.3).
BSA (m2) X 70 mg/m2 = Loading Dose 
Telesna površina (m2) X 70 mg/m2 = uvajalni odmerek
Your doctor will determine the duration of your treatment and how much Caspofungin Accord you will be given each day. 
Zdravnik bo določil trajanje zdravljenja in dnevni odmerek zdravila Kaspofungin Accord.
In a retrospective study of 40 patients treated during marketed use with caspofungin and cyclosporin for 1 to 290 days (median 17.5 days), no serious hepatic adverse reactions were noted. 
V retrospektivni študiji pri 40 bolnikih, ki so med trženjem zdravila dobivali kaspofungin in ciklosporin 1 do 290 dni (mediana 17,5 dni), niso opazili resnih neželenih učinkov na jetra.
Cardiac disorders tachycardia 
Srčne bolezni tahikardija
When caspofungin is co-administered to paediatric patients (12 months to 17 years of age) with inducers of drug clearance, such as rifampicin, efavirenz, nevirapine, phenytoin, dexamethasone, or carbamazepine, a caspofungin dose of 70-mg/m2 daily (not to exceed an actual daily dose of 70 mg) should be considered. 
Če se kaspofungin uporablja pri pediatričnih bolnikih (starih od 12 mesecev do 17 let) sočasno z induktorji očistka zdravila, kakršni so rifampicin, efavirenz, nevirapin, fenitoin, deksametazon ali karbamazepin, je treba razmisliti o uporabi kaspofungina v odmerku 70 mg/m2 na dan (pri čemer pa absolutni dnevni odmerek ne sme preseči 70 mg).
Patients who met the entry criteria and received one or more doses of caspofungin study therapy were included in the efficacy analysis. 
V analizo učinkovitosti so vključili bolnike, ki so ustrezali vključitvenim kriterijem in ki so prejeli enega ali več odmerkov kaspofungina tekom študije.
The white to off-white compact lyophilised powder will dissolve completely. 
Beli do skoraj beli kompaktni liofilizirani prašek se bo popolnoma raztopil.
The response rates among patients with pulmonary disease and extrapulmonary disease were 47 % (21/45) and 28 % (5/18), respectively. 
Delež odziva na zdravljenje je pri bolnikih s pljučno boleznijo znašal 47 % (21/45), pri bolnikih z zunaj-pljučno boleznijo pa 28 % (5/18).
Studies in vitro show that caspofungin is not an inhibitor of any enzyme in the cytochrome P450 (CYP) system. 
Študije in vitro kažejo, da kaspofungin ne zavira nobenega od encimov sistema citokrom P450 (CYP).
• Decreased flow of bile, enlarged liver, yellowing of the skin and/or whites of the eyes, liver injury caused by a drug or chemical, liver disorder 
• zmanjšano izločanje žolča, povečana jetra, porumenitev kože in/ali beločnic v očeh, okvara jeter zaradi zdravil ali kemikalij, motnje v delovanju jeter
• If you have any further questions, ask your doctor, nurse or pharmacist. 
• Če imate dodatna vprašanja, se posvetujte z zdravnikom, medicinsko sestro ali farmacevtom.
dose, the AUC0-24 hr was somewhat higher. 
50 mg/m2, pa je bila AUC0-24h nekoliko večja.
In patients weighing more than 80 kg, after the initial 70 mg loading dose, caspofungin 70 mg daily is recommended (see section 5.2). 
Pri bolnikih, težjih od 80 kg, po začetnem uvajalnem odmerku 70 mg priporočamo kaspofungin v odmerku 70 mg dnevno (glejte poglavje 5.2).
Investigations blood potassium decreased, blood albumin decreased blood creatinine increased, red blood cells urine positive, protein total decreased, protein urine present, prothrombin time prolonged, prothrombin time shortened, blood sodium decreased, blood sodium increased, blood calcium decreased, blood calcium increased, blood chloride decreased, blood glucose increased, blood magnesium decreased, blood phosphorus decreased, blood phosphorus increased, blood urea increased, activated partial thromboplastin time prolonged, blood bicarbonate decreased, blood chloride increased, blood potassium increased, blood pressure increased, blood uric acid decreased, blood urine present, breath sounds abnormal, carbon dioxide decreased, immunosuppressant drug level increased, international normalised ratio increased, urinary casts, white blood cells urine positive, and pH urine increased. 
Preiskave znižane vrednosti kalija v krvi, znižane vrednosti albumina v krvi zvišanje kreatinina v krvi, prisotnost eritrocitov v urinu, znižane vrednosti celokupnih beljakovin, prisotnost beljakovin v urinu, podaljšan protrombinski čas, skrajšan protrombinski čas, znižane vrednosti natrija v krvi, zvišane vrednosti natrija v krvi, znižane vrednosti kalcija v krvi, zvišane vrednosti kalcija v krvi, znižane vrednosti klorida v krvi, zvišane vrednosti glukoze v krvi, znižane vrednosti magnezija v krvi, znižane vrednosti fosforja v krvi, zvišane vrednosti fosforja v krvi, zvišane vrednosti sečnine v krvi, podaljšan aktivirani parcialni tromboplastinski čas, znižane vrednosti hidrogenkarbonata v krvi, zvišane vrednosti klorida v krvi, zvišane vrednosti kalija v krvi, zvišanje krvnega tlaka, znižane vrednosti sečne kisline v krvi, prisotnost krvi v urinu, nenormalni zvoki pri dihanju, znižanje ogljikovega dioksida, zvišane vrednosti imunosupresivov, povišano internacionalno normalizirano razmerje, cilindri v urinu, prisotnost levkocitov v urinu in zvišan pH urina.
Calculation of Body Surface Area (BSA) for paediatric dosing 
Izračun telesne površine za pediatrično odmerjanje
70 mg (from two 50 mg vials)** 
70 mg (iz dveh 50 ml vial)
Unopened vials: store in a refrigerator 2°C - 8°C). 
Neodprte viale: shranjujte v hladilniku (2 C - 8 C).
In a multiple-dose study, a dose reduction of the daily dose to 35 mg in adult patients with moderate hepatic impairment has been shown to provide an AUC similar to that obtained in adult subjects with normal hepatic function receiving the standard regimen (see section 4.2). 
V študiji z večkratnimi odmerki je bila AUC pri odraslih bolnikih z zmerno jetrno okvaro po zmanjšanju dnevnega odmerka na 35 mg podobna kot AUC pri odraslih preiskovancih z normalnim delovanjem jeter, ki so dobivali običajen odmerek (glejte poglavje 4.2).
People who might get this type of infection include those having chemotherapy, those who have had a transplant and those whose immune systems are weak. 
Med tiste, ki bi lahko oboleli za to okužbo, spadajo bolniki, ki prejemajo kemoterapijo, bolniki po transplantaciji ali tisti, ki imajo oslabel imunski sistem.
There is no clinical experience in adult patients with severe hepatic impairment and in paediatric patients with any degree of hepatic impairment. 
Kliničnih izkušenj pri odraslih bolnikih s hudo jetrno okvaro in pri pediatričnih bolnikih s katerokoli stopnjo jetrne okvare ni.
In a second study, patients with invasive candidiasis received daily doses of caspofungin at 50 mg/day (following a 70-mg loading dose on Day 1) or caspofungin at 150 mg/day (see section 4.8). 
V drugi študiji so bolniki z invazivno kandidiazo dnevno prejemali kaspofungin v odmerku 50 mg/dan (po uvajalnem odmerku 70 mg na 1. dan) ali 150 mg/dan (glejte poglavje 4.8).
Pharmacokinetic data from one 10-month old child receiving the 50 mg/m2 daily dose indicated an AUC0-24 hr within the same range as that observed in older children and adults at the 50 mg/m2 and the 50 mg dose, respectively, while in one 6-month old child receiving the 50 mg/m2 
Farmakokinetični podatki so pri enem 10-mesečnem otroku, ki je dobival 50 mg/m2 na dan, pokazali AUC0-24h v enakem območju, kot je bila pri starejših otrocih med uporabo 50 mg/m2 in odraslih med uporabo 50-mg odmerka, pri enem 6-mesečnem otroku, ki je dobival
Close monitoring of liver enzymes should be considered if the two medicinal products are used concomitantly. 
Pri sočasni uporabi teh dveh zdravil je treba razmisliti o skrbnem spremljanju vrednosti jetrnih encimov.
In a retrospective study of 40 patients treated during marketed use with caspofungin and cyclosporin for 1 to 290 days (median 17.5 days), no serious hepatic adverse reactions were noted (see section 4.4). 
V retrospektivni študiji pri 40 bolnikih, ki so se med trženjem zdravila zdravili s kaspofunginom in ciklosporinom 1 do 290 dni (mediana 17,5 dni), niso zabeležili resnih neželenih učinkov na jetra (glejte poglavje 4.4).
Patients in the caspofungin group experienced breakthrough infections due to the following uncommon yeasts and moulds: Trichosporon species (1), Fusarium species (1), Mucor species (1), and Rhizopus species (1). 
Bolniki v kaspofunginski skupini so doživeli izbruh okužbe z naslednjimi redkimi vrstami kvasovk in plesni: Trichosporon (1),
• Empirical therapy for presumed fungal infections (such as Candida or Aspergillus) in febrile, 
• Empirično zdravljenje domnevnih glivnih okužb (npr. s Candido ali Aspergillusom) pri febrilnih, nevtropeničnih odraslih ali pediatričnih bolnikih.
EUCAST breakpoints have not yet been established for caspofungin, due to significant inter-laboratory variation in MIC ranges for caspofungin. 
Zaradi znatnih razlik v razponu MIC vrednosti za kaspofungin med različnimi laboratoriji mejne vrednosti EUCAST za kaspofungin še niso bile določene.
Caspofungin undergoes spontaneous degradation to an open ring compound. 
Kaspofungin se spontano razgradi v spojino z odprtim obročem.
• Decreased haemoglobin (decreased oxygen carrying substance in the blood), decreased white blood cells 
• zmanjšana vrednost hemoglobina (zmanjšana koncentracija snovi, ki prenaša kisik po krvi),
This reconstituted solution may be stored for up to 24 hours at or below 25°C. 
Tako pripravljeno raztopino lahko shranite za največ 24 ur pri temperaturi 25 C ali manj.
• Tightening of the bands of muscle around the airways resulting in wheezing or coughing, fast breathing rate, shortness of breath that wakes you up, shortage of oxygen in the blood, abnormal breath sounds, crackling sounds in the lungs, wheezing, nasal congestion, cough, throat pain 
• piskanje in kašljanje, do katerega pride zaradi zategovanja mišic okrog dihalnih poti, pospešeno dihanje, kratka sapa, ki vas zbudi, pomanjkanje kisika v krvi, nenavadni zvoki pri dihanju, prasketajoči zvoki v pljučih, piskanje, zamašen nos, kašelj, boleče grlo
For all indications, a single 70-mg/m2 loading dose (not to exceed an actual dose of 70 mg) should be administered on Day 1, followed by 50 mg/m2 daily thereafter (not to exceed an actual dose of 70 mg daily). 
Za vse indikacije je treba 1. dan uporabiti en uvajalni odmerek 70 mg/m2 (vendar absolutni odmerek ne sme preseči 70 mg), čemur sledi uporaba 50 mg/m2 dnevno (pri čemer absolutni odmerek ne sme preseči 70 mg na dan).
• Changes in some laboratory blood tests (increased values of some liver tests) 
• spremembe nekaterih laboratorijskih izvidov krvi (povečanje vrednosti nekaterih jetrnih testov)
Caspofungin reduced the trough concentration of tacrolimus by 26 % in healthy adult volunteers. 
Kaspofungin je pri zdravih odraslih prostovoljcih zmanjšal koncentracijo takrolimusa, izmerjeno tik pred naslednjim odmerkom, za 26 %.
However, paediatric patients probably have a different adverse event profile compared to adult patients. 
Vendar pa je profil neželenih učinkov pri pediatričnih bolnikih drugačen kot pri odraslih.
In paediatric patients, results from regression analyses of pharmacokinetic data suggest that co-administration of dexamethasone with caspofungin may result in clinically meaningful reductions in caspofungin trough concentrations. 
Rezultati regresijske analize farmakokinetičnih podatkov pri pediatričnih bolnikih kažejo, da lahko sočasna uporaba deksametazona in kaspofungina klinično pomembno zmanjša koncentracijo kaspofungina, izmerjeno tik pred naslednjim odmerkom.
PHARMACEUTICAL FORM AND CONTENTS Powder for concentrate for solution for infusion. 
FARMACEVTSKA OBLIKA IN VSEBINA prašek za koncentrat za raztopino za infundiranje 1 viala
Alternatively, the volume (mL)c of reconstituted 
Druga možnost je, da količino (ml)c pripravljene raztopine zdravila
Day 1 [not to exceed 70 mg daily]) to liposomal amphotericin B (3 mg/kg IV daily) in a 2:1 treatment fashion (56 on caspofungin, 26 on liposomal amphotericin B) as empirical therapy in paediatric patients with persistent fever and neutropenia. 
na dan) v razmerju zdravljenja 2:1 (56 na kaspofunginu, 26 na liposomskem amfotericinu B) kot empirično zdravljenje pediatričnih bolnikov z dolgotrajno zvišano telesno temperaturo in nevtropenijo.
• The other ingredients are sucrose, mannitol, succinic acid and sodium hydroxide (please see section 2. 
• Druge sestavine zdravila so: saharoza, manitol, jantarna kislina in natrijev hidroksid (prosimo,
Similarly, C. parapsilosis isolates intermediate to anidulafungin and micafungin can be regarded intermediate to caspofungin. 
Podobno se izolate C. parapsilosis, intermediarne za anidulafungin in mikafungin, upošteva kot intermediarne za kaspofungin.